Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 17 of 17

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Retina July 2024

OCT Biomarkers in Ocular CLN2 Disease in Patients Treated With Intraventricular Enzyme Replacement Therapy

PDF

Wei Chieh Huang; Christina M. Ohnsman; Yevgeniya Atiskova; Paulo Falabella; Martin S. Spitzer; Angela Schulz; Simon Dulz
TAGS: biological markers, enzyme replacement therapy, retinal degeneration, fovea centralis, parafoveal region
Invest. Ophthalmol. Vis. Sci.. 2024; 65(8):45. https://doi.org/10.1167/iovs.65.8.45

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2024

Longitudinal assessment of the retinal phenotype in patients with Fabry disease undergoing enzyme replacement and/or chaperone therapy

Jan Einar Wildner; Simon Dulz; Johannes Birtel; Nicole Muschol; Yevgeniya Atiskova

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):188.

ARVO Annual Meeting Abstract June 2024

Real-World efficacy and safety of dexamethasone and fluocinolone acetonide intravitreal implants in patients with non-infectious uveitis

Aydin Özen; Carsten Grohmann; Yevgeniya Atiskova; Martin Stephan Spitzer; Nicole Stuebiger; Johannes Birtel

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2622.

ARVO Annual Meeting Abstract June 2023

Chorioretinal atrophy in mucopolysaccharidosis type 1

Yevgeniya Atiskova; Jan Wildner; Nicole Muschol; Simon Dulz

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):1518.

ARVO Annual Meeting Abstract June 2023

Treatment of a novel CLN2 patient-derived in vitro ocular model with RGX-381 gene therapy prevents or reverses lysosomal waste accumulation

Kwi Hye Kim; Serena Corti; Kevin Achberger; Ryan Reddinger; Chris Tully; Wei Chieh Huang; Yevgeniya Atiskova; Stefan Liebau; Angela Schulz; Simon Dulz; Peter Loskill; Nicholas Buss; Michele Fiscella; Paulo Falabella; Christina Ohnsman

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3851.

ARVO Annual Meeting Abstract June 2023

A modified Pediatric Eye Questionnaire (PedEyeQ) to determine quality of life and functional vision among patients with late-infantile CLN2 disease

Simon Dulz; Martin Stephan Spitzer; Yevgeniya Atiskova

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4122.

ARVO Annual Meeting Abstract June 2022

Comparison of EZ Loss Evaluation with Low- and High-resolution SD-OCT in Classic CLN2 Disease

Wei Chieh Huang; Christina Ohnsman; Yevgeniya Atiskova; Simon Dulz

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3324 – F0133.

ARVO Annual Meeting Abstract June 2022

Longitudinal Results and Test-Retest Variability of a Novel Optokinetic Nystagmus-Based Visual Acuity Test in Children with CLN2 Disease

Christina Ohnsman; Yevgeniya Atiskova; Jan Wildner; Angela Schulz; Simon Dulz

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):4266.

ARVO Annual Meeting Abstract June 2022

Progressive retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in classic late-infantile CLN2 disease

Yevgeniya Atiskova; Christoph Schwering; Jan Wildner; Christoph Spartalis; Frank Schüttauf; Udo Bartsch; Eva Wibbeler; Miriam Nickel; Martin Spitzer; Angela Schulz; Simon Dulz

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):4526 – F0313.

ARVO Annual Meeting Abstract June 2022

The challenge of treating the severest forms of chronic non-infectious posterior and panuveitis

Christoph Spartalis; Nicole Stübiger; Martin Spitzer; Udo Bartsch; Yevgeniya Atiskova

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3203 – A0429.

ARVO Annual Meeting Abstract June 2021

Pilot Study of Novel Optokinetic Nystagmus-Based Visual Acuity Test in Children with CLN2 Disease

Christina M. Ohnsman; Yevgeniya Atiskova; Jan Wildner; Boaz Konig; Angela Schulz; Simon Dulz

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3141.

ARVO Annual Meeting Abstract June 2021

OCT Biomarkers in Ocular CLN2 Disease

Wei Chieh Huang; Yevgeniya Atiskova; Christina M. Ohnsman; Simon Dulz

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):2448.

ARVO Annual Meeting Abstract June 2020

A clinical grading scale to assess ocular involvement in juvenile CLN3 disease

Simon Dulz; Jan Wildner; Christoph Schwering; Miriam Nickel; Eva Wibbeler; Martin S Spitzer; Angela schulz; Yevgeniya Atiskova

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1054.

ARVO Annual Meeting Abstract July 2019

Oxalate retinopathy is irreversible despite early combined liver-kidney transplantation in primary hyperoxaluria type 1

Yevgeniya Atiskova; Simon Dulz; Jun Oh; Enke Grabhorn; Markus Kemper; Florian Brinkert

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):4503.

ARVO Annual Meeting Abstract July 2019

Retinal degeneration in patients with CLN2 disease

Simon Dulz; Christoph Schwering; Eva Wibbeler; Miriam Nickel; Martin Spitzer; Angela Schulz; Yevgeniya Atiskova

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3618.

ARVO Annual Meeting Abstract July 2019

Ocular phenotype and associations with systemic findings in patients with primary hyperoxaluria type I

Johannes Birtel; Philipp Herrmann; Sander F. Garrelfs; Simon Dulz; Yevgeniya Atiskova; Roselie M. Diederen; Martin Gliem; Florian Brinkert; Frank G Holz; Camiel Boon; Bernd Hoppe; Peter Charbel Issa

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5424.

ARVO Annual Meeting Abstract July 2018

Retinal degeneration in a mouse model of neuronal ceroid lipofuscinosis type 1 (CLN1)

Yevgeniya Atiskova; Tatyana Danyukova; Elke Becker; Susanne Bartsch; Christian Hagel; Stephan Storch; Udo Bartsch

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):6073.

Advertisement